Effects of prolonged drug exposure on P-glycoprotein-associated resistance widely differ for various cytotoxic agents
Anna Lång(Oslo University Hospital), M. Lehnert(Merck & Co., Inc., Rahway, NJ, USA (United States)), Dieter Köberle(Kantonsspital St. Gallen), Rita de Giuli(Kantonsspital St. Gallen)
Cited by 0
Related Papers
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.
|PubMed|1996|388
Clinical multidrug resistance in cancer: A multifactorial problem
|European Journal of Cancer|1996|178